Logo image of CTOR

CITIUS ONCOLOGY INC (CTOR) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CTOR - US17331Y1091 - Common Stock

1.13 USD
-0.02 (-1.31%)
Last: 12/26/2025, 8:00:00 PM
1.11 USD
-0.02 (-1.77%)
After Hours: 12/26/2025, 8:00:00 PM
Fundamental Rating

2

CTOR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. CTOR has a bad profitability rating. Also its financial health evaluation is rather negative. CTOR has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CTOR has reported negative net income.
CTOR had a positive operating cash flow in the past year.
CTOR Yearly Net Income VS EBIT VS OCF VS FCFCTOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

CTOR has a Return On Assets (-45.54%) which is in line with its industry peers.
CTOR's Return On Equity of -128.91% is on the low side compared to the rest of the industry. CTOR is outperformed by 61.89% of its industry peers.
Industry RankSector Rank
ROA -45.54%
ROE -128.91%
ROIC N/A
ROA(3y)-20.16%
ROA(5y)N/A
ROE(3y)-21.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTOR Yearly ROA, ROE, ROICCTOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -5 -10 -15 -20 -25

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CTOR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTOR Yearly Profit, Operating, Gross MarginsCTOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

There is no outstanding debt for CTOR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CTOR Yearly Shares OutstandingCTOR Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 20M 40M 60M
CTOR Yearly Total Debt VS Total AssetsCTOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -1.80, we must say that CTOR is in the distress zone and has some risk of bankruptcy.
CTOR's Altman-Z score of -1.80 is in line compared to the rest of the industry. CTOR outperforms 51.13% of its industry peers.
CTOR has a debt to FCF ratio of 5.53. This is a neutral value as CTOR would need 5.53 years to pay back of all of its debts.
CTOR has a better Debt to FCF ratio (5.53) than 91.89% of its industry peers.
A Debt/Equity ratio of 0.12 indicates that CTOR is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.12, CTOR is not doing good in the industry: 63.96% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 5.53
Altman-Z -1.8
ROIC/WACCN/A
WACCN/A
CTOR Yearly LT Debt VS Equity VS FCFCTOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

A Current Ratio of 0.35 indicates that CTOR may have some problems paying its short term obligations.
CTOR has a worse Current ratio (0.35) than 93.58% of its industry peers.
A Quick Ratio of 0.02 indicates that CTOR may have some problems paying its short term obligations.
CTOR has a Quick ratio of 0.02. This is amonst the worse of the industry: CTOR underperforms 97.74% of its industry peers.
Industry RankSector Rank
Current Ratio 0.35
Quick Ratio 0.02
CTOR Yearly Current Assets VS Current LiabilitesCTOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 1M 2M 3M 4M 5M

More info and screens

1

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CTOR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 89.47% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y115%
EPS Next 2Y89.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CTOR Yearly Revenue VS EstimatesCTOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 20M 40M 60M 80M 100M
CTOR Yearly EPS VS EstimatesCTOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 0 0.2 -0.2 0.4 -0.4

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

CTOR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 22.16, CTOR is valued on the expensive side.
Based on the Price/Forward Earnings ratio, CTOR is valued cheaper than 93.77% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.46. CTOR is around the same levels.
Industry RankSector Rank
PE N/A
Fwd PE 22.16
CTOR Price Earnings VS Forward Price EarningsCTOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, CTOR is valued cheaply inside the industry as 91.32% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 137.2
EV/EBITDA N/A
CTOR Per share dataCTOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

CTOR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CTOR's earnings are expected to grow with 89.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y89.47%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CTOR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CITIUS ONCOLOGY INC

NASDAQ:CTOR (12/26/2025, 8:00:00 PM)

After market: 1.11 -0.02 (-1.77%)

1.13

-0.02 (-1.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-23 2025-12-23/amc
Earnings (Next)02-12 2026-02-12
Inst Owners0.68%
Inst Owner Change3656.16%
Ins Owners0.03%
Ins Owner Change8.37%
Market Cap94.37M
Revenue(TTM)N/A
Net Income(TTM)-41.76M
Analysts82.86
Price Target6.12 (441.59%)
Short Float %6.41%
Short Ratio0.53
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)13.94%
Min EPS beat(2)-19.83%
Max EPS beat(2)47.71%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)100%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 22.16
P/S N/A
P/FCF 137.2
P/OCF 137.2
P/B 2.91
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.34
EYN/A
EPS(NY)0.05
Fwd EY4.51%
FCF(TTM)0.01
FCFY0.73%
OCF(TTM)0.01
OCFY0.73%
SpS0
BVpS0.39
TBVpS-0.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -45.54%
ROE -128.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-20.16%
ROA(5y)N/A
ROE(3y)-21.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 5.53
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.35
Quick Ratio 0.02
Altman-Z -1.8
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y115%
EPS Next 2Y89.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-69.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1152.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1152.71%
OCF growth 3YN/A
OCF growth 5YN/A

CITIUS ONCOLOGY INC / CTOR FAQ

What is the ChartMill fundamental rating of CITIUS ONCOLOGY INC (CTOR) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CTOR.


Can you provide the valuation status for CITIUS ONCOLOGY INC?

ChartMill assigns a valuation rating of 5 / 10 to CITIUS ONCOLOGY INC (CTOR). This can be considered as Fairly Valued.


How profitable is CITIUS ONCOLOGY INC (CTOR) stock?

CITIUS ONCOLOGY INC (CTOR) has a profitability rating of 1 / 10.